Imidacloprid + Permethrin + N-Methylpyrolidone

Verify with FDA CVM →

253 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
253
Total Reports
7
Deaths Reported
280.0%
Death Rate

Active Ingredients

Imidacloprid + Permethrin + N-Methylpyrolidone

Administration Routes

TopicalUnknownOralCutaneousOther

Species Affected

Dog 251
Unknown 1
Cat 1

Most Affected Breeds

Retriever - Labrador 35
Retriever - Golden 14
Chihuahua 13
Crossbred Canine/dog 12
Dog (unknown) 10
Shih Tzu 9
Shepherd Dog - German 7
Pit Bull 7
Boxer (German Boxer) 7
Shepherd Dog - Australian 7

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 53
Lack of efficacy (ectoparasite) - flea 48
Emesis 45
Vomiting 40
Lack of efficacy - NOS 31
Other abnormal test result NOS 17
Behavioural disorder NOS 12
INEFFECTIVE, HOOKS 9
Not eating 8
Seizure NOS 8
Diarrhoea 8
Decreased appetite 8

Outcome Breakdown

Recovered/Normal
106 (42.1%)
Outcome Unknown
98 (38.9%)
Ongoing
31 (12.3%)
Recovered with Sequela
10 (4.0%)
Died
6 (2.4%)
Euthanized
1 (0.4%)

Data Summary

Metric Value
Total adverse event reports 253
Reports involving death 7
Case-fatality rate (reported events) 280.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid + Permethrin + N-Methylpyrolidone Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 253 adverse event reports referencing Imidacloprid + Permethrin + N-Methylpyrolidone, including 7 reports in which the animal died — a 280.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imidacloprid + Permethrin + N-Methylpyrolidone. Reported administration routes include Topical, Unknown, Oral, Cutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid + Permethrin + N-Methylpyrolidone reports are Dog (251 reports), Unknown (1 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (35), Retriever - Golden (14), Chihuahua (13) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid + Permethrin + N-Methylpyrolidone are Lethargy (see also Central nervous system depression in 'Neurological') (53), Lack of efficacy (ectoparasite) - flea (48), Emesis (45), Vomiting (40). Of the 252 reports with a coded outcome, Recovered/Normal is the leading category at 42.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid + Permethrin + N-Methylpyrolidone.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial